Overview
Title
To amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028, and for other purposes.
ELI5 AI
H.R. 3916 is like a plan to make sure that more people can get checked early for breast and cervical cancer, especially those who might have a harder time. It wants to spend a lot of money each year from 2025 to 2029 to help doctors and clinics do this better, and it plans to tell Congress every five years how it's going.
Summary AI
H.R. 3916 aims to amend the Public Health Service Act to continue and enhance the National Breast and Cervical Cancer Early Detection Program from 2024 to 2028. This bill focuses on ensuring proper follow-up care, expanding support activities for cancer screening, reducing disparities in cancer rates among different populations, and reporting progress to Congress every five years. It also authorizes $275 million yearly from 2025 to 2029 for the program's implementation.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary
The bill, titled "Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2024" or the "SCREENS for Cancer Act of 2024," aims to amend the Public Health Service Act. Its focus is on the National Breast and Cervical Cancer Early Detection Program, with changes set for fiscal years 2024 through 2028. The bill proposes improvements to early cancer detection programs, allocating resources to enhance screening services, address health disparities, and ensure better follow-up care for breast and cervical cancer. It further calls for financial appropriations of $275 million annually from 2025 through 2029 and modifies reporting requirements to Congress.
Summary of Significant Issues
A major issue with the bill is the significant financial appropriation. The allocation of $275 million per year for the program requires careful justification to avoid perceptions of unnecessary or wasteful spending. Another concern is the change in reporting frequency from annual to every five years, which could reduce oversight and transparency. Additionally, the use of broad terms such as "evidence-based or evidence-informed strategies" raises concerns about the consistency and effectiveness of the program across various healthcare settings. There is also criticism regarding the lack of defined metrics for accountability, which could hinder the program's assessment and public trust.
Broad Public Impact
The bill's broader impact revolves around improving access to cancer detection and prevention services. By reauthorizing and enhancing the National Breast and Cervical Cancer Early Detection Program, it seeks to reduce the incidence and mortality rates related to these cancers. Public health could benefit from increased screening and early detection opportunities, potentially leading to better health outcomes and reduced healthcare costs over time. However, the substantial financial investment and decreased reporting frequency may lead to concerns about the program's efficiency and transparency.
Impact on Specific Stakeholders
For healthcare providers, the bill could present both opportunities and challenges. Providers may benefit from increased funding and resources to support cancer screening initiatives, yet they could face obstacles due to ambiguous guidelines around implementing "evidence-based or evidence-informed strategies." For patients, particularly women who are traditionally underserved, the amendments could offer improved access to necessary screenings and follow-up services, potentially decreasing health disparities.
On the other hand, policymakers and taxpayer advocates may have concerns over the bill's financial implications and the potential for reduced accountability due to less frequent reporting. Advocacy groups focusing on women's health and cancer prevention may view the bill positively as it aligns with efforts to prioritize early detection and health equity.
In summary, while the SCREENS for Cancer Act of 2024 addresses critical public health needs, it raises questions about accountability, fiscal responsibility, and effective implementation, all of which require careful consideration from stakeholders and the public.
Financial Assessment
In examining the financial aspects of H.R. 3916, one observes a critical feature: the bill authorizes $275 million annually for fiscal years 2025 through 2029 in order to fund and improve the National Breast and Cervical Cancer Early Detection Program. This sizable annual appropriation suggests a significant commitment to expanding and enhancing the program, yet it invites scrutiny regarding its necessity and the potential for financial mismanagement.
Financial Appropriation and Oversight
The authorization of $275 million per year represents a substantial financial commitment by Congress. This level of funding aims to cover enhancements in cancer screening services, improve follow-up care, and address disparities among different population groups. However, given the public's interest in government spending efficiency, it is crucial that this allocation is justified and not viewed as excessive. Without clear financial metrics or accountability measures outlined in Section 2 of the bill, there is a risk that the funding could be perceived as wasteful if outcomes are not transparently tracked or reported.
Reporting Frequency and Transparency
Another notable change in the bill concerns the shift in reporting frequency to Congress from annually to every five years. This change may affect the financial oversight and accountability of the program, diminishing the regularity with which Congress and the public can assess how effectively funds are being utilized. Annual reporting often provides a continuous feedback mechanism which can adjust and align spending with desired outcomes in a timely manner. Less frequent reporting could obscure financial inefficiencies or misallocations until they become systemic issues.
Undefined Implementation Strategies
The bill mentions utilizing "evidence-based or evidence-informed strategies" to enhance cancer screening and follow-up services. While this approach can guide the effective use of allocated funds, the broad and undefined nature of these terms raises concerns. Without precise definitions or criteria, there might be inconsistent interpretations across healthcare settings, potentially leading to varied effectiveness and efficiency in using the allocated $275 million annually.
Overall, H.R. 3916's financial elements underscore a strong commitment to combating breast and cervical cancer, though they warrant careful implementation and transparent reporting to ensure that the considerable funds appropriated yield the intended health benefits and maintain public trust.
Issues
The increase in appropriation to $275,000,000 annually from 2025 through 2029 as stated in Section 2(d) may require justification to ensure it is not excessive or wasteful, given public interest in government spending and financial accountability.
The change in reporting frequency from annually to every 5 years in Section 2(c) could decrease the frequency of oversight and accountability, raising concerns about the program’s transparency and efficiency.
The language in Section 2(a)(1)(F) regarding 'evidence-based or evidence-informed strategies' is broad and undefined, which could lead to inconsistent application across healthcare settings and potentially undermine the program’s effectiveness.
The section 'Short title' does not provide sufficient detail about the contents or implications of the Act, limiting understanding of the legislative intent and potential impacts.
There is a lack of clear language outlining metrics or accountability measures in Section 2 to ensure funds are used effectively and achieve their intended outcomes, which is critical for program evaluation and public trust.
The replacement of some terms such as 'monitor' with 'ensure' in Section 2(a)(1)(D)(i) could be perceived as vague, as 'ensure' may not adequately describe a procedure for accountability.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of the bill states its short title as either the "Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2024" or simply the "SCREENS for Cancer Act of 2024."
2. National breast and cervical cancer early detection program Read Opens in new tab
Summary AI
The text outlines amendments to the Public Health Service Act, focusing on improving breast and cervical cancer detection programs. It includes changes to existing grant requirements, promotes enhanced screening services, aims to reduce disparities in cancer outcomes, modifies reporting requirements to Congress, and authorizes funding for the programs through 2029.
Money References
- (a) Program of grants to States.—Section 1501 of the Public Health Service Act (42 U.S.C. 300k) is amended— (1) in subsection (a)— (A) in paragraph (2), by striking “the provision of appropriate follow-up services and support services such as case management” and inserting “that appropriate follow-up services are provided”; (B) in paragraph (3), by striking “programs for the detection and control” and inserting “for the prevention, detection, and control”; (C) in paragraph (4), by striking “the detection and control” and inserting “the prevention, detection, and control”; (D) in paragraph (5)— (i) by striking “monitor” and inserting “ensure”; and (ii) by striking “; and” and inserting a semicolon; (E) by redesignating paragraph (6) as paragraph (9); (F) by inserting after paragraph (5), the following: “(6) to enhance appropriate support activities to increase breast and cervical cancer screening, such as— “(A) patient navigation; “(B) implementation of evidence-based or evidence-informed strategies proven to increase breast and cervical cancer screening in health care settings; and “(C) facilitating access to health care settings that provide breast and cervical cancer screenings; “(7) to reduce disparities in incidents of and deaths due to breast and cervical cancer in populations with higher than average rates; “(8) to improve access to breast and cervical cancer screening and diagnostic services and reduce related barriers, including factors that relate to negative health outcomes; and”; and (G) in paragraph (9), as so redesignated, by striking “through (5)” and inserting “through (8)”; and (2) by striking subsection (d). (b) Requirements with respect to type and quality of services.—Section 1503 of the Public Health Service Act (42 U.S.C. 300m) is amended— (1) in subsection (a)— (A) in paragraph (1), by striking “that, initially” and all that follows through the semicolon and inserting “that appropriate breast and cervical cancer screening and diagnostic services are provided based on national recommendations; and”; (B) by striking paragraphs (2) and (4); (C) by redesignating paragraph (3) as paragraph (2); and (D) in paragraph (2), as so redesignated, by striking “; and” and inserting a period; and (2) by striking subsection (d). (c) Reports to Congress.—Section 1508(b) of the Public Health Service Act (42 U.S.C. 300n–4(b)) is amended— (1) in the heading, by striking “Report” and inserting “Reports”; (2) by striking “1 year after the date of the enactment of the National Breast and Cervical Cancer Early Detection Program Reauthorization of 2007, and annually thereafter,” and inserting “2 years after the date of enactment of the SCREENS for Cancer Act of 2024, and every 5 years thereafter,”; (3) by striking “Labor and Human Resources” and inserting “Health, Education, Labor, and Pensions”; and (4) by striking “preceding fiscal year” and inserting “preceding 2 fiscal years in the case of the first report after the date of enactment of the SCREENS for Cancer Act of 2024, and preceding 5 fiscal years for each report thereafter,”. (d) Authorization of appropriations.—Section 1510(a) of the Public Health Service Act (42 U.S.C. 300n–5(a)) is amended— (1) by striking “and” after “2011,”; and (2) by inserting “, and $275,000,000 for each of fiscal years 2025 through 2029” before the period at the end. ---